Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Venture Global Inc. Class A common stock (VG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Venture Global Inc. Class A common stock — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Venture Global Inc. Class A common stock trades at $13.29 (market cap $34.60B). The key difference: Venture Global Inc. Class A common stock is far larger — about 4.6× Spyre Therapeutics Inc. Common Stock's market cap, and Venture Global Inc. Class A common stock pays a 1.16% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Venture Global Inc. Class A common stock for 1 Days on average.
| SYRE | VG | |
|---|---|---|
Market Cap | $7.52B | $34.60B |
Volume | 1,441,031 | 11,731,839 |
Sector | Health | Energy |
52-Week High | $108.92 | $17.53 |
52-Week Low | $22.18 | $5.92 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $6.52B | $73.99B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VG trades at $13.84, up 5.41% today, with a bearish technical signal but strong fundamentals including a 21.24% net income margin and 48.13% ROE. Recent earnings have consistently beaten estimates, and the company is expanding LNG capacity to 85 MTPA by 2029, supported by long-term supply deals like the 20-year agreement with ConocoPhillips announced on October 1, 2026.
The stock offers value with a P/E of 10.52 and consensus price target of $16.13, but faces risks from high short interest and negative net cash flow in 2025. Analyst sentiment is bullish with 58% buy ratings, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Venture Global Inc. Class A common stock
Venture Global develops, builds, and operates liquefied natural gas export facilities. Its projects connect U.S. natural gas supply with global LNG markets.
Read more on VG →
